Christian Jackisch Selected Research

Christian Jackisch Research Topics

Disease

128	Breast Neoplasms (Breast Cancer) 02/2022 - 04/2002
41	Neoplasms (Cancer) 11/2022 - 10/2002
13	Pathologic Complete Response 05/2021 - 04/2010
11	Triple Negative Breast Neoplasms 01/2022 - 09/2013
9	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 09/2003
7	Neutropenia 01/2021 - 09/2006
6	Carcinoma (Carcinomatosis) 10/2017 - 12/2003
6	Exanthema (Rash) 01/2016 - 04/2007
5	Diarrhea 10/2021 - 04/2007
5	Cardiotoxicity 06/2021 - 10/2005
5	Febrile Neutropenia 01/2021 - 11/2008
5	Infections 07/2015 - 03/2009
4	Neoplasm Metastasis (Metastasis) 10/2021 - 08/2006
4	Ovarian Epithelial Carcinoma 01/2017 - 08/2006
3	Inflammatory Breast Neoplasms 11/2019 - 01/2010
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2019 - 09/2013
3	Hand-Foot Syndrome 01/2012 - 04/2010
3	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2006 - 10/2004
2	Brain Neoplasms (Brain Tumor) 02/2022 - 01/2010
2	Heart Failure 03/2016 - 03/2010
2	Thrombocytopenia (Thrombopenia) 06/2014 - 07/2013
2	Lobular Carcinoma 02/2014 - 06/2013
2	Hypertension (High Blood Pressure) 09/2013 - 01/2012
2	Disease Progression 01/2006 - 10/2004
1	Body Weight (Weight, Body) 06/2021
1	Overweight 06/2021
1	Premature Birth (Birth, Premature) 02/2021
1	Myocardial Infarction 01/2021
1	Thrombocytosis (Thrombocythemia) 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 02/2019
1	Amenorrhea 01/2019
1	Residual Neoplasm 01/2019

Drug/Important Bio-Agent (IBA)

39	Trastuzumab (Herceptin)FDA Link 01/2022 - 10/2004
24	Hormones (Hormone)IBA 01/2022 - 04/2005
22	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 09/2003
22	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2002
22	human ERBB2 proteinIBA 10/2021 - 01/2006
21	taxaneIBA 01/2021 - 01/2006
17	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 03/2010
15	AnthracyclinesIBA 01/2021 - 01/2009
13	Lapatinib (GW572016)FDA Link 01/2021 - 01/2010
12	Docetaxel (Taxotere)FDA Link 01/2018 - 10/2002
10	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2003
8	130-nm albumin-bound paclitaxelIBA 01/2022 - 04/2012
8	ErbB Receptors (EGF Receptor)IBA 10/2021 - 03/2010
8	Capecitabine (Xeloda)FDA Link 10/2021 - 04/2008
8	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2013 - 10/2002
7	PlatinumIBA 01/2020 - 10/2006
6	pertuzumabIBA 01/2022 - 03/2013
6	Phenobarbital (Luminal)FDA Link 10/2019 - 05/2012
6	Estrogen ReceptorsIBA 01/2018 - 10/2004
6	Bevacizumab (Avastin)FDA Link 10/2017 - 01/2012
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 10/2004
5	Tamoxifen FDA LinkGeneric 12/2008 - 10/2002
4	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 07/2010
4	Biomarkers (Surrogate Marker)IBA 05/2021 - 01/2008
3	Epidermal Growth Factor (EGF)IBA 10/2021 - 02/2014
3	Immunoconjugates (Immunoconjugate)IBA 05/2021 - 01/2019
3	Aromatase InhibitorsIBA 06/2020 - 02/2007
3	Cytotoxins (Cytolysins)IBA 01/2019 - 10/2004
3	AlbuminsIBA 01/2019 - 03/2009
3	Monoclonal AntibodiesIBA 01/2017 - 10/2005
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2006
3	Vinorelbine (Navelbine)FDA LinkGeneric 08/2013 - 04/2008
2	Immune Checkpoint InhibitorsIBA 05/2021 - 05/2021
2	Anastrozole (Arimidex)FDA LinkGeneric 06/2020 - 05/2013
2	Biological ProductsIBA 01/2020 - 08/2015
2	Ado-Trastuzumab EmtansineIBA 01/2019 - 04/2017
2	SolventsIBA 01/2019 - 03/2016
2	Biosimilar PharmaceuticalsIBA 04/2017 - 01/2015
2	Indicators and Reagents (Reagents)IBA 04/2017 - 12/2010
2	ParaffinIBA 10/2016 - 02/2006
2	Pharmaceutical PreparationsIBA 09/2014 - 04/2007
2	Ibandronic Acid (Boniva)FDA Link 10/2013 - 10/2011
2	AntibodiesIBA 03/2013 - 01/2009
2	Taxoids (Taxanes)IBA 04/2012 - 10/2004
2	Gemcitabine FDA Link 09/2010 - 10/2006
2	Tyrosine Kinase InhibitorsIBA 01/2010 - 01/2009
2	SteroidsIBA 01/2009 - 02/2006
2	Estrogen Receptor alphaIBA 03/2005 - 10/2004
1	Denosumab FDA Link 01/2022
1	neratinibIBA 10/2021
1	Cyclin-Dependent Kinase 4IBA 05/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	Maytansine (Maitansine)IBA 01/2019
1	antineoplaston A10 (A 10)IBA 01/2018

Therapy/Procedure

59	Therapeutics 11/2022 - 10/2004
49	Neoadjuvant Therapy 01/2022 - 10/2002
42	Drug Therapy (Chemotherapy) 10/2021 - 09/2003
9	Adjuvant Chemotherapy 01/2017 - 10/2005
4	Radiotherapy 10/2021 - 02/2011
3	Drug Tapering 04/2014 - 09/2006
2	Subcutaneous Injections 01/2022 - 01/2021
2	Operative Surgical Procedures 10/2021 - 11/2006
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2018
2	Intravenous Infusions 01/2021 - 01/2016
2	Mastectomy (Mammectomy) 11/2019 - 01/2010
2	Aftercare (After-Treatment) 11/2018 - 10/2018
1	Palliative Care (Palliative Therapy) 02/2022
1	Pessaries 02/2021